Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
SERS-Based Droplet Microfluidic Platform for Sensitive and High-Throughput Detection of Cancer Exosomes
ACS Sensors ( IF 8.2 ) Pub Date : 2024-09-04 , DOI: 10.1021/acssensors.4c01357 Kwun Hei Willis Ho 1 , Huang Lai 1 , Ruolin Zhang 1 , Haitian Chen 2, 3 , Wen Yin 1 , Xijing Yan 4 , Shu Xiao 1 , Ching Ying Katherine Lam 1 , Yutian Gu 1 , JiaXiang Yan 1 , Kunpeng Hu 4 , Jingyu Shi 1 , Mo Yang 1, 5, 6, 7
ACS Sensors ( IF 8.2 ) Pub Date : 2024-09-04 , DOI: 10.1021/acssensors.4c01357 Kwun Hei Willis Ho 1 , Huang Lai 1 , Ruolin Zhang 1 , Haitian Chen 2, 3 , Wen Yin 1 , Xijing Yan 4 , Shu Xiao 1 , Ching Ying Katherine Lam 1 , Yutian Gu 1 , JiaXiang Yan 1 , Kunpeng Hu 4 , Jingyu Shi 1 , Mo Yang 1, 5, 6, 7
Affiliation
|
Exosomes, nanosized extracellular vesicles containing biomolecular cargo, are increasingly recognized as promising noninvasive biomarkers for cancer diagnosis, particularly for their role in carrying tumor-specific molecular information. Traditional methods for exosome detection face challenges such as complexity, time consumption, and the need for sophisticated equipment. This study addresses these challenges by introducing a novel droplet microfluidic platform integrated with a surface-enhanced Raman spectroscopy (SERS)-based aptasensor for the rapid and sensitive detection of HER2-positive exosomes from breast cancer cells. Our approach utilized an on-chip salt-induced gold nanoparticles (GNPs) aggregation process in the presence of HER2 aptamers and HER2-positive exosomes, enhancing the hot spot-based SERS signal amplification. This platform achieved a limit of detection of 4.5 log10 particles/mL with a sample-to-result time of 5 min per sample. Moreover, this platform has been successfully applied for HER2 status testing in clinical samples to distinguish HER2-positive breast cancer patients from HER2-negative breast cancer patients. High sensitivity, specificity, and the potential for high-throughput screening of specific tumor exosomes make this SERS-based droplet system a potential liquid biopsy technology for early cancer diagnosis.
中文翻译：
基于 SERS 的液滴微流控平台，用于癌症外泌体的灵敏和高通量检测
外泌体是含有生物分子货物的纳米级细胞外囊泡，越来越多地被认为是用于癌症诊断的有前途的非侵入性生物标志物，特别是因为它们在携带肿瘤特异性分子信息方面的作用。传统的外泌体检测方法面临复杂性、耗时和需要精密设备等挑战。本研究通过引入一种新型液滴微流体平台来解决这些挑战，该平台与基于表面增强拉曼光谱 (SERS) 的适体传感器集成，用于快速、灵敏地检测乳腺癌细胞中的 HER2 阳性外泌体。我们的方法在 HER2 适体和 HER2 阳性外泌体存在的情况下利用片上盐诱导金纳米粒子 (GNP) 聚集过程，增强基于热点的 SERS 信号放大。该平台的检测限为 4.5 log 10颗粒/mL，每个样品的样品到结果时间为 5 分钟。此外，该平台已成功应用于临床样本的HER2状态检测，以区分HER2阳性乳腺癌患者和HER2阴性乳腺癌患者。高灵敏度、特异性以及对特定肿瘤外泌体进行高通量筛选的潜力，使得这种基于 SERS 的液滴系统成为用于早期癌症诊断的潜在液体活检技术。
更新日期：2024-09-04
中文翻译：
基于 SERS 的液滴微流控平台，用于癌症外泌体的灵敏和高通量检测
外泌体是含有生物分子货物的纳米级细胞外囊泡，越来越多地被认为是用于癌症诊断的有前途的非侵入性生物标志物，特别是因为它们在携带肿瘤特异性分子信息方面的作用。传统的外泌体检测方法面临复杂性、耗时和需要精密设备等挑战。本研究通过引入一种新型液滴微流体平台来解决这些挑战，该平台与基于表面增强拉曼光谱 (SERS) 的适体传感器集成，用于快速、灵敏地检测乳腺癌细胞中的 HER2 阳性外泌体。我们的方法在 HER2 适体和 HER2 阳性外泌体存在的情况下利用片上盐诱导金纳米粒子 (GNP) 聚集过程，增强基于热点的 SERS 信号放大。该平台的检测限为 4.5 log 10颗粒/mL，每个样品的样品到结果时间为 5 分钟。此外，该平台已成功应用于临床样本的HER2状态检测，以区分HER2阳性乳腺癌患者和HER2阴性乳腺癌患者。高灵敏度、特异性以及对特定肿瘤外泌体进行高通量筛选的潜力，使得这种基于 SERS 的液滴系统成为用于早期癌症诊断的潜在液体活检技术。
京公网安备 11010802027423号